INCYIncyte

Each row is one issuer’s token for Incyte, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.

Tokenized versions of Incyte, the issuer behind each, the chains it is deployed on, and what these wallets hold of it.

Token	Issuer	Chains	You hold
INCYx	xStocks	HYPEBNBTONINKSOLARBMNTXLYROPETH	—

Deployments come from the instrument registry, generated 2026-09-30. A chain listed here is one the issuer has deployed on, not a promise that a market exists on it.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Type

Common stock

Sector

Healthcare › Pharmaceuticals

Exchange

Nasdaq

Listed since

Nov 3, 1993

Shares outstanding

202.7M

Employees

2,844

As the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.